Biotech & Binary Event Investor, Fund Manager, Macro-trends Analyst, ex. MIT Researcher,Physics Ph.D., Chief Investment Officer at Red Acre Investments
$UNH confirmed in their ASM remarks that Q2 call would provide revised 2025 guidance and outlook for 2026.
We called this timing on 5/22. (See https://t.co/Qg7OM9xVlB)
There's one more key date coming up next week.
Get Ahead of the Curve.
Quick question for my investing tweets: what's the hardest thing for you right now when it comes to picking stocks and growing your portfolio?
What's holding you back the most?
@bio_clouseau Disagreement on assay sub mission timeline is notable: "the company and the FDA have not been able to agree on bluebird bio providing data regarding these assays to the FDA during review of the BLA. " $BLUE
Hmm.. I love Tim Horton's coffee.. but why is it so frequently bought with toilet paper 🤔🤔🤔. The perils of modern #BigData we learn associations like this.